1. Scrip
  2. >>Archive

Ophthotech Appoints CFO

 
• By Lubna Ahmed

Ophthotech Corporation has appointed Glenn P. Sblendorio executive vice president, chief operating officer and chief financial officer (CFO) – effective April 1, 2016. The company also announced that the current executive vice president and chief financial and business officer, Michael G. Atieh will be retiring – effective April 1, 2016. Sblendorio will be joining Ophthotech from The Medicines Company, where he most recently served as president and CFO. Previously he held various senior management positions at Hoffmann-La Roche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC.

Ophthotech Corporation has appointed Glenn P. Sblendorio executive vice president, chief operating officer and chief financial officer (CFO) – effective April 1, 2016. The company also announced that the current executive vice president and chief financial and business officer, Michael G. Atieh will be retiring – effective April 1, 2016. Sblendorio will be joining Ophthotech from The Medicines Company, where he most recently served as president and CFO. Previously he held various senior management positions at Hoffmann-La Roche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.